# Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma

> **NCT00210041** · PHASE2 · COMPLETED · sponsor: **Institut Claudius Regaud** · enrollment: 50 (estimated)

## Conditions studied

- Genital Neoplasms, Male

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT00210041
- **Lead sponsor:** Institut Claudius Regaud
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2011-12
- **Final completion:** 2012-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00210041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00210041, "Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00210041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*